ACTA1 and scleroderma: As shown in Fig. 5b, e, g, i, the number of α-SMA+ myofibroblasts was evidently increased in the scleroderma skin of BLM-treated mice (P < 0.001) but was reduced to normal levels in the EV-treated mice (P < 0.001).